Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 5, 2015, Pages 235-244

  Stewart, Suzanne B ^a   Boorjian, Stephen A ^a  

^a DEPARTMENT OF UROLOGY   (United States)

Author keywords

High risk; Prostate cancer; Prostatectomy; Treatment

Indexed keywords

ADVANCED CANCER; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; COMPARATIVE EFFECTIVENESS; DIAGNOSTIC ACCURACY; GLEASON SCORE; HIGH RISK PATIENT; HIGH RISK PROSTATE CANCER; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURGICAL APPROACH; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW (TOPIC); PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME;

HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 84929263377     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.10.003     Document Type: Review

References (79)

1. Cooperberg M.R., Cowan J., Broering J.M., Carroll P.R. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008, 26:211-218.
2. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 1998, 280:969-974.
3. Thompson I., Thrasher J.B., Aus G., Burnett A.L., Canby-Hagino E.D., Cookson M.S., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007, 177:2106-2131.
4. Mohler JL KP, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline): Prostate Cancer. 2.2014 ed: NCCN.org; 2014.
5. Cooperberg M.R., Freedland S.J., Pasta D.J., Elkin E.P., Presti J.C., Amling C.L., et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006, 107:2384-2391.
6. Meng M.V., Elkin E.P., Latini D.M., Duchane J., Carroll P.R. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005, 173:1557-1561.
7. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-106.
8. Roach M., Bae K., Speight J., Wolkov H.B., Rubin P., Lee R.J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26:585-591.
9. Fallon B., Williams R.D. Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 1990, 17:853-866.
10. Hortobagyi G.N., Blumenschein G.R., Spanos W., Montague E.D., Buzdar A.U., Yap H.Y., et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983, 51:763-768.
11. Hortobagyi G.N., Ames F.C., Buzdar A.U., Kau S.W., McNeese M.D., Paulus D., et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988, 62:2507-2516.
12. Consensus statement/NIH Consensus Development Conference National Institutes of Health Consensus Development Conference 1990, 8:1-25. Adjuvant therapy for patients with colon and rectum cancer.
13. Shanta V., Krishnamurthi S., Sastry D.V., Menon R. Multimodal approach in the therapy of stage III female breast cancers. J Surg Oncol 1985, 28:134-136.
14. Kantarjian H.M., Hortobagyi G.N., Smith T.L., Blumenschein G.R., Montague E., Buzdar A.U., et al. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol 1984, 20:1353-1361.
15. Wolmark N., Wieand H.S., Hyams D.M., Colangelo L., Dimitrov N.V., Romond E.H., et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000, 92:388-396.
16. Yossepowitch O., Eggener S.E., Bianco F.J., Carver B.S., Serio A., Scardino P.T., et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007, 178:493-499. [discussion 499].
17. Reese A.C., Sadetsky N., Carroll P.R., Cooperberg M.R. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer 2011, 117:283-289.
18. Grossfeld G.D., Chang J.J., Broering J.M., Li Y.P., Lubeck D.P., Flanders S.C., et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001, 165:851-856.
19. Mitchell C.R., Boorjian S.A., Umbreit E.C., Rangel L.J., Carlson R.E., Karnes R.J. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int 2012, 110:1709-1713.
20. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005, 95:751-756.
21. Epstein J.I., Feng Z., Trock B.J., Pierorazio P.M. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012, 61:1019-1024.
22. Boorjian S.A., Karnes R.J., Crispen P.L., Rangel L.J., Bergstralh E.J., Sebo T.J., et al. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol 2009, 181:95-104. [discussion 104].
23. Afaq A., Koh D.M., Padhani A., van As N., Sohaib S.A. Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int 2011, 108:1716-1722.
24. Giannarini G., Petralia G., Thoeny H.C. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 2012, 61:326-340.
25. Seitz M., Shukla-Dave A., Bjartell A., Touijer K., Sciarra A., Bastian P.J., et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009, 55:801-814.
26. D'Amico A.V., Denham J.W., Crook J., Chen M.H., Goldhaber S.Z., Lamb D.S., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25:2420-2425.
27. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
28. Boorjian S.A., Karnes R.J., Rangel L.J., Bergstralh E.J., Blute M.L. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008, 179:1354-1360. [discussion 1360-1].
29. Thompson I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. J Am Med Assoc 2006, 296:2329-2335.
30. Wiegel T., Bottke D., Steiner U., Siegmann A., Golz R., Storkel S., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
31. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781-1788.
32. Siddiqui S.A., Boorjian S.A., Inman B., Bagniewski S., Bergstralh E.J., Blute M.L. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol 2008, 179:1830-1837. ([discussion 1837]).
33. Siddiqui S.A., Boorjian S.A., Blute M.L., Rangel L.J., Bergstralh E.J., Karnes R.J., et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int 2011, 107:383-388.
34. Sanda M.G., Dunn R.L., Michalski J., Sandler H.M., Northouse L., Hembroff L., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
35. Frazier H.A., Robertson J.E., Paulson D.F. Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival?. World J Urol 1994, 12:308-312.
36. Nam R.K., Cheung P., Herschorn S., Saskin R., Su J., Klotz L.H., et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol 2014, 15:223-231.
37. Thompson I.M., Tangen C., Basler J., Crawford E.D. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002, 168:1008-1012.
38. Engel J., Bastian P.J., Baur H., Beer V., Chaussy C., Gschwend J.E., et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010, 57:754-761.
39. Steuber T., Budaus L., Walz J., Zorn K.C., Schlomm T., Chun F., et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 2011, 107:1755-1761.
40. Cadeddu J.A., Partin A.W., Epstein J.I., Walsh P.C. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 1997, 50:251-255.
41. Ghavamian R., Bergstralh E.J., Blute M.L., Slezak J., Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+prostate cancer: a matched comparison. J Urol 1999, 161:1223-1227. [discussion 1227-8].
42. Yossepowitch O., Eggener S.E., Serio A.M., Carver B.S., Bianco F.J., Scardino P.T., et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008, 53:950-959.
43. Hsu C.Y., Joniau S., Oyen R., Roskams T., Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007, 51:121-128. [discussion 128-9].
44. Boorjian S.A., Karnes R.J., Rangel L.J., Bergstralh E.J., Frank I., Blute M.L. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int 2008, 101:299-304.
45. Loeb S., Schaeffer E.M., Trock B.J., Epstein J.I., Humphreys E.B., Walsh P.C. What are the outcomes of radical prostatectomy for high-risk prostate cancer?. Urology 2010, 76:710-714.
46. Inman B.A., Davies J.D., Rangel L.J., Bergstralh E.J., Kwon E.D., Blute M.L., et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level>or =50 ng/mL. Cancer 2008, 113:1544-1551.
47. Spahn M., Joniau S., Gontero P., Fieuws S., Marchioro G., Tombal B., et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010, 58:1-7. [discussion 10-1].
48. Boorjian S.A., Thompson R.H., Siddiqui S., Bagniewski S., Bergstralh E.J., Karnes R.J., et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007, 178:864-870. [discussion 870-1].
49. Abdollah F., Karnes R.J., Suardi N., Cozzarini C., Gandaglia G., Fossati N., et al. Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol 2014, 65:554-562.
50. Lane J.A., Hamdy F.C., Martin R.M., Turner E.L., Neal D.E., Donovan J.L. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010, 46:3095-3101.
51. Boorjian S.A., Karnes R.J., Viterbo R., Rangel L.J., Bergstralh E.J., Horwitz E.M., et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011, 117:2883-2891.
52. Zelefsky M.J., Eastham J.A., Cronin A.M., Fuks Z., Zhang Z., Yamada Y., et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010, 28:1508-1513.
53. Tewari A., Divine G., Chang P., Shemtov M.M., Milowsky M., Nanus D., et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy-a propensity scoring approach. J Urol 2007, 177:911-915.
54. Albertsen P.C., Hanley J.A., Penson D.F., Barrows G., Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 2007, 177:932-936.
55. Abdollah F., Schmitges J., Sun M., Jeldres C., Tian Z., Briganti A., et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol 2012, 19:836-844. [author reply 44-5].
56. Cooperberg M.R., Vickers A.J., Broering J.M., Carroll P.R. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010, 116:5226-5234.
57. Abdollah F., Sun M., Thuret R., Jeldres C., Tian Z., Briganti A., et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011, 59:88-95.
58. Hoffman R.M., Koyama T., Fan K.H., Albertsen P.C., Barry M.J., Goodman M., et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst. 2013, 105:711-718.
59. Fletcher S.G., Mills S.E., Smolkin M.E., Theodorescu D. Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:1092-1099.
60. Arcangeli G., Strigari L., Arcangeli S., Petrongari M.G., Saracino B., Gomellini S., et al. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75:975-982.
61. Akakura K., Suzuki H., Ichikawa T., Fujimoto H., Maeda O., Usami M., et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 2006, 36:789-793.
62. Kupelian P.A., Elshaikh M., Reddy C.A., Zippe C., Klein E.A. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002, 20:3376-3385.
63. Resnick M.J., Koyama T., Fan K.H., Albertsen P.C., Goodman M., Hamilton A.S., et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013, 368:436-445.
64. Tefilli M.V., Gheiler E.L., Tiguert R., Barroso U., Barton C.D., Wood D.P., et al. Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer. J Surg Oncol 1998, 69:156-161.
65. Chen B.T., Wood D.P. Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer. Urology 2003, 62(Suppl. 1):69-78.
66. Schmitges J., Trinh Q.D., Walz J., Graefen M. Surgery for high-risk localized prostate cancer. Ther Adv Urol 2011, 3:173-182.
67. Berglund R.K., Jones J.S., Ulchaker J.C., Fergany A., Gill I., Kaouk J., et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology 2006, 67:1253-1256.
68. Novara G., Ficarra V., D'Elia C., Secco S., Cioffi A., Cavalleri S., et al. Evaluating urinary continence and preoperative predictors of urinary continence after robot assisted laparoscopic radical prostatectomy. J Urol 2010, 184:1028-1033.
69. Lowrance W.T., Eastham J.A., Savage C., Maschino A.C., Laudone V.P., Dechet C.B., et al. Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol 2012, 187:2087-2092.
70. Punnen S., Meng M.V., Cooperberg M.R., Greene K.L., Cowan J.E., Carroll P.R. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer?. BJU Int 2013, 112:E314-E320.
71. Krambeck A.E., DiMarco D.S., Rangel L.J., Bergstralh E.J., Myers R.P., Blute M.L., et al. Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int 2009, 103:448-453.
72. Ritch C.R., You C., May A.T., Herrell S.D., Clark P.E., Penson D.F., et al. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology 2014, 83:1309-1315.
73. Yuh B., Artibani W., Heidenreich A., Kimm S., Menon M., Novara G., et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol 2014, 65:918-927.
74. Gandaglia G., Sammon J.D., Chang S.L., Choueiri T.K., Hu J.C., Karakiewicz P.I., et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol 2014, 32:1419-1426.
75. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., Myers R.P., Blute M.L. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 2004, 172:1328-1332.
76. Abdollah F., Gandaglia G., Suardi N., Capitanio U., Salonia A., Nini A., et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol 2014, [Epub ahead of print].
77. Budaus L., Spethmann J., Isbarn H., Schmitges J., Beesch L., Haese A., et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8,916 European patients treated within the last decade. BJU Int 2011, 108:1256-1261.
78. Lowrance W.T., Elkin E.B., Yee D.S., Feifer A., Ehdaie B., Jacks L.M., et al. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int 2012, 109:1309-1314.
79. Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014, 65:124-137.